Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Rakovina Therapeutics Inc

RKV.V ✓ COMPLIANT ☆ Track — members

TSX Venture · Healthcare · Biotechnology & Medical Research ·

Canada Micro Cap Analyst: N/A

Last Close

$0.15

▲ +5.13%

Market Cap $3.62M · Vol 32.00K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.62M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

71.43

Momentum

Beta

0.08

vs Market

52W High

$0.38

61.32% below

52W Low

$0.06

138.37% above

Volume

32.00K

Avg 27.44K

P/B

15.14

Price-to-book

ROE

N/A

Return on equity

Free Float

89.75%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Rakovina Therapeutics Inc (RKV.V) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does RKV.V pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+7.89%

+86.36%

+46.43%

+32.26%

YTD

+105.00%

-59.00%

-80.81%

-88.92%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-6,325,109.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-165.64% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	15.14
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	24.41M

Technical Indicators

50-Day SMA	$0.10
200-Day SMA	$0.09
RSI (14)	71.43
Beta	0.08
52-Week High	$0.38
52-Week Low	$0.06

Volume Today	32.00K
Avg Daily Volume (30D)	27.44K
Relative Volume	1.17x
Volatility (10D)	161.20
Volatility (30D)	137.55
Free Float	89.75%

Analyst Consensus

N/A

Current Price $0.15

Mean Target N/A

52W Low$0.06 52W High$0.38

Current

Target

$0.06 $0.38

Current Analyst target

· 0 analysts

Identifiers

ExchangeTSX Venture

FIGIBBG00BN3WGZ4

ISINCA75103L3092

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd +3.29% ARGX.BR argenx SE +1.74% ARGX argenx SE +0.83% 2269.HK WuXi Biologics (Cayman) Inc +7.41% INSM Insmed Inc -0.07%

Company Profile

Rakovina Therapeutics Inc. is a Canada-based biopharmaceutical research company. It is focused on the development of cancer treatments based on deoxyribonucleic acid (DNA)-damage response powered by Artificial Intelligence (AI) using the proprietary Deep-Docking and Enki platforms. Its drug development pipeline includes kt-2000AI and kt-3000 series. It is engaged in employing the proprietary Deep Docking AI Platform to rapidly screen billions of potential drug candidates against PARP (kt-2000AI) and other novel DDR targets to generate drug candidates that can be advanced to human trials or developed in collaboration with pharmaceutical partners. Its kt-3000 series represents a novel class of bi-functional small-molecule drug candidates that has been designed to combine inhibition of both poly (ADP)-ribose polymerase (PARP) and histone deacetylase in a single molecule. This novel approach has the potential to overcome treatment resistance and provide clinical benefit to cancer patients.